Moderna reported a quarterly loss of $1.18 per share, beating the Zacks Consensus Estimate for a $3.02 loss and improving from a $2.52 loss a year ago. The narrower-than-expected loss suggests better-than-anticipated operating performance, though the company remains unprofitable. The result is likely to support the stock modestly, but the news is limited to earnings and does not include guidance or revenue figures.
Moderna reported a quarterly loss of $1.18 per share, beating the Zacks Consensus Estimate for a $3.02 loss and improving from a $2.52 loss a year ago. The narrower-than-expected loss suggests better-than-anticipated operating performance, though the company remains unprofitable. The result is likely to support the stock modestly, but the news is limited to earnings and does not include guidance or revenue figures.
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request DemoOverall Sentiment
moderately positive
Sentiment Score
0.35
Ticker Sentiment
